Daiichi Sankyo
Daiichi sheds more US jobs as generic losses take their toll
October 20, 2015Daiichi, Daiichi Sankyo, generic competition, generics, job losses, patent cliff, patents, redundancies
The Japan-based drugmaker Daiichi Sankyo is to cut up to 1,200 jobs – or about half its workforce – in …
NICE recommends Daiichi’s Lixiana for blood clots
July 13, 2015Sales and Marketing DVT, Daiichi, Daiichi Sankyo, Lixiana, NICE, NOACs, VTE, anticoagulant, blood clots, edoxaban, novel anticoagulant. PE
Daiichi Sankyo has won a speedy approval from NICE, after the NHS guidance body approved its newly-launched blood clotting drug …
Daiichi Sankyo launches clotting drug Lixiana in UK
July 10, 2015Medical Communications, Sales and Marketing Daiichi Sankyo, Lixiana, NOAC, VTE, anticoagulant, atrial fibrillation, blood clots, edoxaban, novel anticoagulant, strokes, warfarin
Daiichi Sankyo’s Lixiana has become the latest pharma offering in the class of newer oral anticoagulants in the UK.Lixiana (edoxaban) …
Merck to test Keytruda combinations
May 8, 2015Sales and Marketing BMS, Daiichi Sankyo, Merck, Plexxikon, keytruda, pembrolizumab
Merck will be teaming up with Daiichi Sankyo’s subsidiary Plexxikon to investigate immunotherapy combinations in cancer. A collaborative clinical trial …
Daiichi Sankyo to sell Sun Pharma stake
April 21, 2015Manufacturing and Production, Sales and Marketing Daiichi Sankyo, FDA, India, Ranbaxy, Sun Pharma, generics
Daiichi Sankyo is to sell off all or part of its stake in Sun Pharma and back away from the …
Daiichi Sankyo cuts 16% of US staff
March 27, 2015Sales and Marketing Benicar, Daiichi Sankyo, FDA, Ranbaxy, Welchol, ambit, colesevelam, cuts, olmesartan
Daiichi Sankyo is laying off 16% of its staff at its US commercial headquarters as the company braces itself for …
Sun Pharma completes Ranbaxy acquisition
March 26, 2015Manufacturing and Production, Sales and Marketing Daiichi Sankyo, India, Ranbaxy, Sun Pharma, cci
Sun Pharma has closed its mega merger deal with Ranbaxy and begun the integration of the two businesses. The combined …
Daiichi-Sankyo pays $39m to settle allegations
January 12, 2015Sales and Marketing Azor, Benicar, Daiichi Sankyo, Daiichi-Sankyo, Tribenzor, Welchol, kickbacks, us justice
Daiichi-Sankyo will pay the US government and state Medicaid programmes $39 million to resolve claims that it violated the False …
Daiichi-Sankyo blood drug gets FDA nod
January 12, 2015Sales and Marketing BMS, Daiichi Sankyo, Daiichi-Sankyo, FDA, Pfizer, Pradaxa, atrial fibrillation, blood, savaysa
The US Food and Drug Administration has shown Daiichi-Sankyo’s anti-clotting drug Savaysa the green light to reduce the risk of …
Daiichi Sankyo pays $410m for Ambit Biosciences
September 29, 2014Sales and Marketing AML, Daiichi Sankyo, ambit biosciences, quizartinib
Daiichi Sankyo has bought San Diego-based Ambit Biosciences in a deal aimed at shoring up the Japanese company’s cancer research. …
Ranbaxy hit with second generic Lipitor recall
March 10, 2014Manufacturing and Production, Sales and Marketing Daiichi Sankyo, FDA, Ranbaxy, hamburg, manufacturing
India’s largest native generic drugmaker Ranbaxy has come under greater pressure this week after the US has again sent out …
Daiichi Sankyo hires two new executives
October 7, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Daiichi Sankyo
Daiichi Sankyo has appointed Glenn Gormley to be its corporate president and chairman, and Greg Barrett as a new acting …
Edoxaban ‘as effective as warfarin’
September 2, 2013Sales and Marketing DVT, Daiichi Sankyo, VTE, warfarin
Daiichi Sankyo is celebrating after its once-a-day blood thinner edoxaban proved as effective as warfarin in a late-stage trial, although …
Glass particles force recall of Ranbaxy Lipitor
November 27, 2012Manufacturing and Production, Sales and Marketing Daiichi Sankyo, Lipitor, Pfizer, Ranbaxy, recall
Ranbaxy Pharmaceuticals is recalling around 40 batches of its generic atorvastatin tablets after discovering that some of the product may …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
